OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
January 11, 2021
How PREP Act protections will apply to potential COVID-19 vaccine-related claims.
November 18, 2020
Whether your company already has a data-driven compliance program in place or is contemplating building one, Michael O'Connor and Isha Arora outline four things the DOJ is now focused on that your compliance team needs to know.
August 10, 2020
How pharma leaders can convert data collected for compliance purposes from a cost center into a critical success factor.
July 08, 2020
Amid the limitations of traditional compliance programs that emphasize control measures, here are steps biopharma companies can implement in their own cultures to ensure they’re behaving and performing with integrity.
July 01, 2020
Case study illustrates how compliance teams, in today’s climate, can foster innovation across an organization to help achieve corporate goals.
June 26, 2020
Xavier Duburcq describes how pharma leaders can convert compliance from a cost center to a critical success factor.
March 18, 2020
It is vital to begin asking questions about your company’s DSCSA readiness and compliance, as well as that of your strategic partners, writes Rob Besse.
August 21, 2019
Is Congress harming pharmaceutical research by limiting enforcement of improvement patents?
July 13, 2019
How pharma companies can bolster their quality management programs to meet FDA’s evolving compliance requirements.
May 08, 2019
Op-Ed: The best way to capitalize on the potential revenue influx from enterprise-level drug adherence programs is to create room at the executive table for a Chief Adherence Officer.